917474-59-0

Usage

Uses

Used in Pharmaceutical Research and Drug Discovery:
5-BOC-AMINOINDAZOLE is used as a building block for the synthesis of potential drug candidates due to its ability to be easily deprotected and incorporated into complex organic molecules. This feature makes it instrumental in the development of new medications and therapies.
Used in Organic Synthesis:
As a protected amine group compound, 5-BOC-AMINOINDAZOLE is used as an intermediate in the synthesis of various heterocyclic compounds, which are essential in the creation of a wide range of organic molecules with different properties and applications.
Used as a Precursor for Biologically Active Compounds:
5-BOC-AMINOINDAZOLE serves as a precursor in the synthesis of biologically active compounds, contributing to the development of molecules with specific biological functions and potential therapeutic uses.
Overall, 5-BOC-AMINOINDAZOLE is a significant compound in the field of medicinal and pharmaceutical chemistry, playing a crucial role in the advancement of new chemical entities and therapeutic agents.

InChI:InChI=1/C12H15N3O2/c1-12(2,3)17-11(16)14-9-4-5-10-8(6-9)7-13-15-10/h4-7H,1-3H3,(H,13,15)(H,14,16)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 19335-11-6 1H-indazol-5-ylamine 

Downstream Products

• 1338793-95-5 2-ethoxy-2-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide 
• 1338792-51-0 (R)-2-methoxy-2-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide 
• 1338818-06-6 (S)-2-methoxy-2-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide 
• 1338792-50-9 2-methoxy-2-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide 
• 1338794-32-3 2-cyclohexyl-2-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide 
• 1338794-29-8 2-cyclopentyl-2-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide 
• 1338792-75-8 3-methyl-2-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)butanamide 
• 1338792-71-4 (±)-2-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)butanamide 

Relevant academic research and scientific papers

1-(5-Carboxyindazol-1-yl)propan-2-ones as dual inhibitors of cytosolic phospholipase A2α and fatty acid amide hydrolase: bioisosteric replacement of the carboxylic acid moiety

Indazole-5-carboxylic acids with 3-aryloxy-2-oxopropyl residues in position 1 were previously reported to be potent dual inhibitors of cytosolic phospholipase A2α (cPLA2α) and fatty acid amide hydrolase (FAAH). In continuation of our structure-activity studies on cPLA2α and FAAH inhibitors, a number of derivatives of these substances characterized by bioisosteric replacement of the carboxylic acid functionality by inverse amides, sulfonylamides, carbamates and ureas were prepared. The biological evaluation of the obtained compounds showed that the carboxylic acid functionality of the lead compounds is of special importance for a pronounced inhibition of cPLA2α and FAAH.

NOVEL INDAZOLECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS COMPRISING THEM AND THEIR USE FOR PRODUCING MEDICAMENTS

The present application relates to novel 6-substituted indazoles having a carboxamide side chain, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing me

The discovery of orally bioavailable tyrosine threonine kinase (TTK) inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as anticancer agents

The acetamido and carboxamido substituted 3-(1H-indazol-3-yl)benzenesulfonamides are potent TTK inhibitors. However, they display modest ability to attenuate cancer cell growth; their physicochemical properties, and attendant pharmacokinetic parameters, a

Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides

TTK kinase was identified by in-house siRNA screen and pursued as a tractable, novel target for cancer treatment. A screening campaign and systematic optimization, supported by computer modeling led to an indazole core with key sulfamoylphenyl and acetamido moieties at positions 3 and 5, respectively, establishing a novel chemical class culminating in identification of 72 (CFI-400936). This potent inhibitor of TTK (IC50 = 3.6 nM) demonstrated good activity in cell based assay and selectivity against a panel of human kinases. A co-complex TTK X-ray crystal structure and results of a xenograft study with TTK inhibitors from this class are described.

INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as T

KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The present teachings provide a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Also described are a pharmaceutical composition and method of use thereof.

SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

Substituted cyclopropyl compounds of the formula I: are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.

A mild and selective method for the N-Boc deprotection by sodium carbonate

A cleavage of N-tert-butyloxycarbonyl protection by Na2CO3 is reported. The N-free products are obtained in excellent yields. The compatibility of the method with the presence of acidic or basic groups is demonstrated. The reactions were performed on indole, azaindole, indazole, pyrazole, indolinone, quinolinone, and oxazolone.